AML-202 QuANTUM-First: Efficacy by Age in Newly Diagnosed (nd) Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)
Harry P. Erba(Michigan Center for Translational Pathology), Pau Montesinos(Instituto de Salud Carlos III), Arnaud Lesegretain(Daiichi Sankyo (United States)), Alexander E. Perl(University of Pennsylvania), Richard F. Schlenk(German Cancer Research Center), Mikkael A. Sekeres(University of Miami), Elżbieta Patkowska(Institute for Transfusion Medicine), Abderrahmane Laadem(Daiichi Sankyo (India)), Yasser Mostafa Kamel(Daiichi Sankyo (United States)), Karima Imadalou(Daiichi Sankyo (United States)), Sergio Amadori(Polyclinic Medical Center), Jianxiang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Mark J. Levis(Sidney Kimmel Cancer Center), Hervé Dombret(University of London Institute in Paris), Li Liu(Daiichi Sankyo (United States)), Jörge E. Cortes(Augusta University Health)
Cited by 1
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k